August 22, 2023
A Japanese health ministry panel on August 21 backed regulatory approval for a throng of new medicines, including Novartis Pharma’s inclisiran, which would become the first siRNA therapy for dyslipidemia in the country, if approved. Inclisiran, marketed as Leqvio in...read more